Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Betamethasone

FDA-approved product (tablet, oral), marketed as Celestone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Betamethasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Eye inflammation
  • Hemorrhoid
  • Nasal congestion

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Corticosteroids acting locally; Corticosteroids; Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Betamethasone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Betamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound

    NCT00655512 · start 2008-01

    Registered record
    Registry ID
    NCT00655512
    Conditions
    Healthy
    Interventions
    pimecrolimus 1% cream; hydrocortisonacetat 1% cream; betamethasonvalerat 0,1% cream; clobetasol-17-propionat 0,05% cream; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionpimecrolimus 1% cream; hydrocortisonacetat 1% cream; betamethasonvalerat 0,1% cream; clobetasol-17-propionat 0,05% cream +1 more
    PhasePhase 1
    Registry statusCompleted

  • Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

    NCT00470392 · start 2007-05

    Registered record
    Registry ID
    NCT00470392
    Conditions
    Psoriasis
    Interventions
    Imiquimod; Clobetasol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2007-05
    Completion
    2012-07
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionImiquimod; Clobetasol
    PhaseNot applicable
    Registry statusTerminated

  • Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

    NCT00263718 · start 2005-12

    Registered record
    Registry ID
    NCT00263718
    Conditions
    Psoriasis Vulgaris
    Interventions
    Calcipotriol plus betamethasone dipropionate (LEO 80185) gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-12
    Completion
    2006-05
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    InterventionCalcipotriol plus betamethasone dipropionate (LEO 80185) gel
    PhasePhase 2
    Registry statusCompleted

  • Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams

    NCT00800293 · start 2002-12

    Registered record
    Registry ID
    NCT00800293
    Conditions
    Healthy
    Interventions
    Betamethasone Dipropionate 0.05% Cream
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-01
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBetamethasone Dipropionate 0.05% Cream
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)

    NCT01512901

    Registered record
    Registry ID
    NCT01512901
    Conditions
    Macular Edema Following Branch Retinal Vein Occlusion
    Interventions
    Betamethasone Microsphere (DE-102） Low Dose; Betamethasone Microsphere (DE-102） High Dose; Sham
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Edema Following Branch Retinal Vein Occlusion
    InterventionBetamethasone Microsphere (DE-102） Low Dose; Betamethasone Microsphere (DE-102） High Dose; Sham
    PhasePhase 2 / Phase 3
    Registry statusCompleted